The European Commission announced on Wednesday that it was in advanced negotiations to reach an agreement with the Biontech-Pfizer alliance for an order for 200 million doses of a future vaccine against Covid-19.
It is the fifth pharmaceutical laboratory with which Brussels is close to concluding a contract.
So far the negotiations have only been successful with the British AstraZeneca for an order of 300 million doses and, according to our information, at a price of 336 million euros!
The United States, for its part, has concluded no less than six agreements for millions of doses and for a total of 9.2 billion euros.
Gigantic sums indeed, while it is absolutely not sure that the research is successful ...
But the states are ready to make these investments, because the economic stakes are colossal.
The Covid-19 pandemic has caused an economic crisis unprecedented since World War II and the main remedy to end it appears to be a vaccine.
Each state therefore wants to ensure that it can vaccinate its population as quickly as possible.
But this research is very expensive and so is the production of the doses.
States therefore prefer to advance the costs in order to save their population and their economy in record time.
The summary of the week
France 24 invites you to come back to the news that marked the week
I subscribe
Take international news everywhere with you!
Download the France 24 application
google-play-badge_FR